Sampford Advisors Inc’s Post

View organization page for Sampford Advisors Inc, graphic

2,565 followers

The biopharma sector is currently experiencing a shift and particular interest in artificial intelligence, with a focus on integrating these capabilities into drug discovery and development, and obesity treatments.   In 2023, the biopharma venture capital exit landscape declined from a dollar perspective to US$18.3bn versus US$23.6bn in 2022 but increased from a deal volume perspective to 94 transactions versus 77 in 2022. Exit activity over the last two years is marked by a preference for more mature clinical data compared to the market environment in 2021 which also supported exits for companies with only preliminary clinical data. Notable exits include RayzeBio's US$4.1bn acquisition by Bristol Myers Squibb and Carmot's US$2.9bn acquisition by Roche.

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics